Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2010

View Archived Issues

Enrollment progresses in phase IIb vidofludimus trial in rheumatoid arthritis

Capsaicin-mediated TRPV1 activation may help battle hypertension

Researchers describe new mPTP inhibitors

Aviptadil does not improve pulmonary vascular resistance in phase II trial in PAH

Polymorphic variants in HTR2A gene may predict extent of musculoskeletal pain

Agenix progresses preclinical development of hepatitis B drug AGX-1009

Addex raises funds to further develop ADX-48621

Wintherix elects WX-04554 as lead drug for bone healing

FDA accepts Eisai's NDA for Aricept transdermal patch for review

FDA committee recommends approval of Vivitrol for opioid dependence

VX-770 shows promise in patients with cystic fibrosis

FDA advisory committee does not recommend approval of lorcaserin for obesity

Merck & Co. identifies new glucagon receptor antagonists

Janssen Pharmaceutica claims new phosphodiesterase 10A ligands

FDA awards grant to AGTC for phase II trial in Leber's congenital amaurosis

Prometheus and Tarrot Laboratories to identify biomarkers of response to anti-TNF drugs for CD

New York University discloses novel antibacterial agents

Genfit advances GFT-505 to phase II in type 2 diabetes

BioCryst Pharmaceuticals' BCX-4208 shows efficacy in gout

Urifer claims new heterocyclic compound for cancer therapy

Galderma discloses new ACAT-1 inhibitors

ISTA initiates two studies in phase III program for Remura in dry eye disease

European and U.S. regulatory submissions planned for Zolmitriptan RapidFilm

Oramed Pharma reports data from exploratory study of oral insulin capsule

Phase II trial begins for SG-2000 in ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...